{'fraction_non_alphanumeric': 0.011312217194570135, 'fraction_numerical': 0.0, 'mean_word_length': 5.514705882352941, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Role of Reimbursement in the Adoption of Continuous Glucose Monitors

Continuous glucose monitors are a clinically meaningful addition to treatment plans for patients with diabetes who are actively managing their care. Since they first became commercially available, much progress has been made to ensure coverage of these devices for patients, but inadequate reimbursement of clinicians' time continues to serve as a barrier to adoption.